Kaufman G E, Paidas M J
Department of Obstetrics and Gynecology, New England Medical Center, Boston, MA 02111.
Semin Perinatol. 1994 Aug;18(4):333-49.
Significant progress has unquestionably occurred in the diagnosis and treatment of fetal and neonatal alloimmune thrombocytopenia. However, fundamental aspects of this disease are still not fully understood, especially those factors that account for the diverse clinical spectrum of this disease. This impacts our ability to counsel patients regarding the ultimate outcome of fetuses affected with AIT. IVIG appears to be a promising treatment for fetuses affected with this disease. In all likelihood, fetuses affected with AIT are at higher risk for serious bleeding complications related to fetal blood sampling procedures, but this risk remains to be further defined.
胎儿和新生儿同种免疫性血小板减少症的诊断和治疗无疑已取得显著进展。然而，这种疾病的基本方面仍未完全了解，尤其是那些导致该疾病临床谱多样化的因素。这影响了我们就患有同种免疫性血小板减少症（AIT）胎儿的最终结局向患者提供咨询的能力。静脉注射免疫球蛋白（IVIG）似乎是治疗患有这种疾病胎儿的一种有前景的方法。很有可能，患有AIT的胎儿因胎儿血样采集程序而发生严重出血并发症的风险更高，但这一风险仍有待进一步明确。
